Pratosartan

Drug Profile

Pratosartan

Alternative Names: DA 727; KD 3671; KT 3671

Latest Information Update: 12 May 2015

Price : $50

At a glance

  • Originator Kotobuki Seiyaku
  • Developer Boryung Pharmaceutical; Daiichi Sankyo Company; Kotobuki Pharmaceutical
  • Class Antihypertensives; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hypertension
  • Discontinued Atherosclerosis; Diabetic nephropathies; Glomerulonephritis

Most Recent Events

  • 13 Apr 2012 Pratosartan is still in phase III development in South Korea and phase II in Japan for Hypertension
  • 10 Sep 2010 Clinical development is ongoing in Japan and South Korea
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top